Edgar Filing: Revance Therapeutics, Inc. - Form 4

Revance The Form 4	erapeutics, Inc.										
November 1	7, 2015										
EODM 4										OMB APPROVAL	
CURIVI 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										3235-0287	
Check th if no long	ter									January 31, 2005	
subject to STATEMENT OF CHAN Section 16. Form 4 or				SECUR	ITIES				Estimated a burden hou response	verage	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type I	Responses)										
Bertolino Arthur Peter Symbol				ssuer Name and Ticker or Trading ool ance Therapeutics, Inc. [RVNC]				5. Relationship of Reporting Person(s) to Issuer			
(Leat)	(First)			•		с. [К	VNCJ	(Check all applicable)			
				of Earliest Transaction /Day/Year) /2015				Director 10% Owner X Officer (give title Other (specify below) below)			
BOULEVA								EVP and C	hief Medical C	officer	
(Street) 4. If Amer				endment, Date Original				6. Individual or Joint/Group Filing(Check			
Filed(Mor NEWARK, CA 94560				nth/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	rities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			ed of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)		
C				Code V	Amount		Price	(Instr. 3 and 4)			
Common Stock	11/17/2015			S <u>(1)</u>	5,425	D	\$ 39.11	36,329	D		
Common Stock	11/17/2015			S <u>(1)</u>	36	D	\$ 39.55	36,293	D		
Common Stock	11/17/2015			S <u>(2)</u>	2,277	D	\$ 39.11	34,016	D		
Common Stock	11/17/2015			S <u>(2)</u>	15	D	\$ 39.55	34,001	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Unde Secur	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
Bertolino Arthur Peter C/O REVANCE THERAPEUTICS, 7555 GATEWAY BOULEVARD NEWARK, CA 94560	INC.		EVP and Chief Medical Officer					
Signatures								
/s/ Gordon Ho, Attorney-in-fact	11/17/2015							

**Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Reporting Person sold an aggregate of 5,461 shares of restricted stock to settle a personal tax liability in connection with the (1) November 15, 2015 vesting of certain shares of restricted stock that the Reporting Person acquired pursuant to a grant dated September 2, 2014.

The Reporting Person sold an aggregate of 2,292 shares of restricted stock to settle a personal tax liability in connection with the (2) November 15, 2015 vesting of certain shares of restricted stock that the Reporting Person acquired pursuant to a grant dated January 28, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.